RCT with 25 nitazoxanide patients and 25 control patients, showing improved virological and clinical outcomes with treatment.
Authors also perform an in vitro
study in Vero E6 cells showing 90% inhibition with 0.5µM, with no cytotoxicity. NCT04348409.
Blum et al., 1/22/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, 20 authors.
risk of death, 66.7% lower, RR 0.33, p = 0.25, treatment 2 of 25 (8.0%), control 6 of 25 (24.0%).
relative severity scores, 20.2% lower, RR 0.80, treatment 25, control 25.
hospitalization time, 32.5% lower, relative time 0.68, p = 0.02, treatment 25, control 25.
risk of no virological cure, 89.8% lower, RR 0.10, p = 0.03, treatment 0 of 23 (0.0%), control 4 of 19 (21.1%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 21.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.